Company profile
Xebra Brands Ltd.
OTC: XBRAF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Vancouver, BCReports USD
#1052 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ —GM —SS 8
v0.1 · 5/100 weight · pillars only
↑ disclosure history, revenue growth (YoY) · ↓ Piotroski F, workforce scale
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$1.4M
Employees
2
as of 2026-08-31
Market cap
$1.5k
as of 2026-08-31
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$79.1k106.9k CAD2024
Net income-$1.4M-2.0M CAD2024
Operating income-$1.2M-1.6M CAD2024
Total assets$279.5k379.4k CAD2024
Liabilities$582.0k790.0k CAD2024
Equity-$113.8k-154.5k CAD2024
Revenue trend
FY2020 – FY2024 · USD
FY20
FY21
FY22
FY23
FY24
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Xebra Brands Ltd.’s revenue?
Xebra Brands Ltd. booked $79.1k in FY2024 revenue, contracting 35% year over year — slower than 77% of Healthcare companies we track, at a -1831.8% net margin.
Peers · Healthcare
Black Bird Biotech, Inc.——U.S. Stem Cell, Inc.——Sera Prognostics, Inc.41DImaging Dynamics Company Ltd.31DNemaura Medical Inc.——RegeneRx Biopharmaceuticals, Inc.——Key facts
CEORodrigo Valencia Gallardo
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersVancouver, BC
ExchangeOTC: XBRAF
Employees2
IPO date2021-11-24
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.